AFT Maxigesic License for Nordics with Wiefa

Market release
12
th
January 2017

New Maxigesic agreement for AFT Pharmaceuticals with Leading Nordic Consumer
Health Company in Sweden, Norway, Finland, Denmark and Iceland

AFT Pharmaceuticals (‘AFT’) has licensed the product line of its patented combination
painkiller,
Maxigesic, in the Nordic region to Weifa AS (‘Weifa’).

Maxigesic consists of a patented fixed ratio of ibuprofen and paracetamol (also called
acetaminophen) for pain management. Maxigesic products will cover tablet, sachet and
oral liquid formulations.

AFT Managing Director, Dr Hartley Atkinson, says “AFT is particularly pleased to expand
its existing relationship with Weifa. With respect to
Maxigesic, Weifa not only has
expertise in the pain management field, but also in consumer health markets across the
Nordic region. These markets are quite sizable, US$165M
1
, and we look forward to
taking substantial market share through our alliance with Weifa. We aim to launch this
coming FY2018.”

“This fits in well with our aim to increase the number of countries that
Maxigesic is
launched in over the next 12-15 months and hence sales. We have now completed two
agreements within the last few weeks and we are working on a significant number of
agreements, so we anticipate further announcements further down the track this year.
This will include some larger size deals ,” said Dr Atkinson.

Kathrine Gamborg Andreassen, Chief Executive Officer at Weifa, says “We are delighted
to sign this new alliance agreement with AFT. Maxigesic represents a unique novelty for
the Nordic market and will contribute greatly to Weifa’s analgesic portfolio. The success

of our Nordic strategy depends on the commercialisation of highly innovative products
which meet the needs of consumers and pharmacies.”


Ferghana Partners (New York, London, Boston) initiated these transactions and provided
strategic/financial advisory services to AFT Pharma.



About Weifa
Weifa is Norway's leading consumer health company. Weifa supplies pharmaceutical
products and lifestyle products that address the essential needs of consumers,
customers and professional partners. The Company has a strong position in Norway and
is the market leader there in pain relief, with well-established brands such as
Paracet
and Ibux, and is also present in other key consumer fields such as intimate care, dietary
supplements and treatment for colds and respiratory problems. Weifa is listed on the
Oslo Stock Exchange and has its head office in Oslo. In 2015, the Group had a turnover
of approximately NOK 332m (after adjusting for the divestment of the B2B business in
APIs).


[End of Release]

For more information:
Hartley Atkinson
Managing Director, AFT Pharmaceuticals Ltd
Phone: +64 9 488 0232

Footnote 1: IMS World Review Pack [Aug 2015] Paracetamol and Ibuprofen tablet
market for Nordic countries but excluding Denmark and Iceland]